Business Context and Reporting Period
Company: Alcon, Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2006
Business Overview: Alcon is a global medical specialty company focused on eye care, developing, manufacturing, and marketing pharmaceuticals, surgical equipment/devices, and consumer eye care products. The company operates through two segments: Alcon United States and Alcon International. It is a majority-owned subsidiary of Nestlé S.A. (approximately 76.4% ownership as of year-end).
Key Financial Metrics (Year Ended Dec 31, 2006)
| Metric | 2006 (in millions) | 2005 (in millions) |
|---|---|---|
| Sales (Revenue) | $4,896.6 | $4,368.5 |
| Gross Profit | $3,681.5 | $3,290.1 |
| Gross Margin | 75.2% | 75.3% |
| Operating Income | $1,572.1 | $1,187.9 |
| Operating Margin | 32.1% | 27.2% |
| Net Earnings | $1,348.1 | $931.0 |
| Diluted EPS | $4.37 | $2.98 |
| Operating Cash Flow | $1,405.9 | $1,235.0 |
| Total Debt | $981.3 | $1,083.4 |
| Cash & Cash Equivalents | $1,489.2 | $1,457.2 |
| Net Cash Position | $507.9 | $373.8 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 12.1% year-over-year, driven by volume growth in most markets. Constant currency sales growth was 11.7%.
- Pharmaceuticals: Sales grew 13.5% to $2.0 billion, led by Vigamox, NEVANAC, and glaucoma products (TRAVATAN).
- Surgical: Sales grew 9.3% to $2.2 billion, driven by intraocular lenses (AcrySof IQ and ReSTOR) and cataract/vitreoretinal products. Refractive sales declined 8.0%.
- Consumer Eye Care: Sales grew 17.4% to $685.6 million, driven by contact lens disinfectants and artificial tears (Systane).
- Profitability: Net earnings increased 44.8% to $1.35 billion. This was significantly aided by a $119.0 million pretax benefit from the reduction of a litigation provision accrued in 2005.
- Impairment Charges: The company recorded $144.8 million in impairment losses related to refractive product line assets ($125.7 million in amortization of intangibles and $19.1 million in cost of goods sold).
- Accounting Changes: Adoption of SFAS No. 123(R) resulted in $83.0 million of share-based compensation expense, reducing net earnings by approximately $55.2 million after tax.
- Litigation Settlement: In July 2006, Alcon settled patent disputes with Advanced Medical Optics, Inc. (AMO) for $121.0 million. This resulted in a $119.0 million benefit in 2006 due to the reversal of a $240.0 million provision recorded in 2005.
Guidance, Outlook, Risks, and Unusual Items
- Product Safety Alert: On February 21, 2007, Alcon issued a Device Safety Alert directing physicians to discontinue CustomCornea wavefront system myopia procedures using the LADAR6000 excimer laser due to reports of "central islands" affecting visual acuity. An investigation is ongoing. Refractive sales represented only 1.1% of total sales in 2006, but future technology fees are expected to be reduced.
- Patent Expirations: Key products face patent expirations, including TobraDex (December 2008) and Patanol (2010). The company is actively developing replacement products and defending patents against generic challenges (e.g., Vigamox and Patanol).
- Dividend Policy: The Board proposed a dividend of CHF 2.50 per share (approx. $2.03) for 2006 earnings, subject to shareholder approval in May 2007. Total estimated payout is $604 million.
- Share Repurchases: The company purchased approximately 8.5 million treasury shares in 2006 for $899.2 million. As of year-end, authorizations remained for approximately 3.4 million additional shares.
- Risks: Significant risks include currency fluctuations (exposure to Euro, Yen, Swiss Franc), regulatory changes in reimbursement (Medicare Part D, EU price controls), and the potential for product recalls or litigation.
Investor Verification Checklist
- Refractive Segment Viability: Verify the impact of the LADAR6000 safety alert on future refractive revenue and the timeline for corrective action.
- Patent Cliff Management: Assess the progress of replacement products for TobraDex and Patanol ahead of their patent expirations.
- Impairment Sustainability: Confirm that the $144.8 million impairment charge was a one-time event and review future cash flow projections for the refractive segment.
- Share-Based Compensation Impact: Monitor the ongoing impact of SFAS No. 123(R) on future operating margins as the company continues to grant equity awards.
- Dividend Approval: Confirm shareholder approval of the proposed CHF 2.50 dividend at the May 2007 annual meeting.